Simple and quickly determinable laboratory parameters may help physicians in countries with lower health budget to identify CHC patients who would achieve a high SVR rate upon an antiviral treatment with Peg-IFN-α and RBV. The gene discussed is IFNA2; the disease is cryohydrocytosis.